Annals of Surgical Oncology

, Volume 15, Issue 9, pp 2426–2432 | Cite as

8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer

  • Vic J. Verwaal
  • Sjoerd Bruin
  • Henk Boot
  • Gooike van Slooten
  • Harm van Tinteren
Gastrointestinal Oncology

Abstract

Introduction

The treatment of peritoneal carcinomatosis is based on cytoreduction followed by hyperthermic intraperitoneal chemotherapy and combined with adjuvant chemotherapy. In 2003, a randomized trial was finished comparing systemic chemotherapy alone with cytoreduction followed by hyperthermic intraperitoneal chemotherapy and systemic chemotherapy. This trial showed a positive result favoring the studied treatment. This trial has now been updated to a minimal follow-up of 6 years to show long-term results.

Patients and Methods

For all patients still alive, the follow-up was updated until 2007. In the original study, four patients were excluded—two because of no eligible histology/pathology and two because of major protocol violations. After randomization, four patients in the HIPEC arm and six in the control arm were not treated using the intended therapy, one patient because of withdrawal, one because of a life-threatening other malignant disease and the others because of progressive disease before initiation of the treatment. During the follow-up, one patient was crossed over from the control arm and underwent cytoreduction and HIPEC for recurrent disease, after the assigned treatment was completed. The data from these patients were censored at the moment of the cross-over. Progression-free and disease-specific survival were analyzed using the Kaplan Meyer test and compared using the log rank method. The long-term results were studied in more detail to evaluate efficacy and toxicity.

Results

At the time of this update, the median follow-up was almost 8 years (range 72–115 months). In the standard arm, 4 patients were still alive, 2 with and 2 without disease; in the “HIPEC’ arm, 5 patients were still alive, 2 with and 3 without disease. The median progression-free survival was 7.7 months in the control arm and 12.6 months in the HIPEC arm (P = 0.020). The median disease-specific survival was 12.6 months in the control arm and 22.2 months in the HIPEC arm (P = 0.028). The 5-year survival was 45% for those patients in whom a R1 resection was achieved.

Conclusion

With 90% of all events having taken place up to this time, this randomized trial shows that cytoreduction followed by HIPEC does significantly add survival time to patients affected by peritoneal carcinomatosis of colorectal origin. For a selected group, there is a possibility of long-term survival.

Key Words

HIPEC Peritoneal carcinomatosis Colorectal cancer Cytoreduction Randomized trial 

References

  1. 1.
    Glehen O, Osinsky D, Beaujard AC, et al. Natural history of peritoneal carcinomatosis from nongynecologic malignancies. Surg Oncol Clin N Am 2003; 12:729–39, xiiiPubMedCrossRefGoogle Scholar
  2. 2.
    Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89:1545–50PubMedCrossRefGoogle Scholar
  3. 3.
    Sugarbaker PH. Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis. Dis Colon Rectum 1994; 37:S115–22PubMedCrossRefGoogle Scholar
  4. 4.
    Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Langenbecks Arch Surg 1999; 384:576–87PubMedCrossRefGoogle Scholar
  5. 5.
    Troisi RJ, Freedman AN, Devesa SS. Incidence of colorectal carcinoma in the U.S.: an update of trends by gender, race, age, subsite, and stage, 1975–1994. Cancer 1999; 85:1670–6PubMedCrossRefGoogle Scholar
  6. 6.
    Yan TD, Chu F, Links M, et al. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival. Eur J Surg Oncol 2006; 32:1119–24PubMedCrossRefGoogle Scholar
  7. 7.
    Sugarbaker PH. A curative approach to peritoneal carcinomatosis from colorectal cancer. Semin Oncol 2005; 32:S68–73PubMedCrossRefGoogle Scholar
  8. 8.
    Sugarbaker PH. Peritonectomy procedures. Cancer Treat Res 2007; 134:247–64PubMedGoogle Scholar
  9. 9.
    Spratt JS, Adcock RA, Sherrill W, et al. Hyperthermic peritoneal perfusion system in canines. Cancer Res 1980; 40:253–5PubMedGoogle Scholar
  10. 10.
    Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22:3284–92PubMedCrossRefGoogle Scholar
  11. 11.
    Bloemendaal AL, Verwaal VJ, van Ruth S, et al. Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: a prospective study. Eur J Surg Oncol 2005; 31:1145–51PubMedCrossRefGoogle Scholar
  12. 12.
    Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88:358–63PubMedCrossRefGoogle Scholar
  13. 13.
    Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21:3737–43PubMedCrossRefGoogle Scholar
  14. 14.
    Witkamp AJ, de Bree E, Van Goethem R, et al.. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 2001; 27:365–74PubMedCrossRefGoogle Scholar
  15. 15.
    Gill S, Thomas RR, Goldberg RM. Review article: colorectal cancer chemotherapy. Aliment Pharmacol Ther 2003; 18:683–92CrossRefGoogle Scholar
  16. 16.
    de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938–47PubMedGoogle Scholar
  17. 17.
    Tabernero J, Van Cutsem E, Diaz-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007; 25:5225–32PubMedCrossRefGoogle Scholar
  18. 18.
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335–42PubMedCrossRefGoogle Scholar
  19. 19.
    de Bree E, Koops W, Kroger R, et al. Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol 2004; 86:64–73PubMedCrossRefGoogle Scholar
  20. 20.
    Folprecht G, Kohne CH, Lutz MP. Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Cancer Treat Res 2007; 134:425–40PubMedGoogle Scholar
  21. 21.
    Baulieu F, Bourlier P, Scotto B, et al. The value of immunoscintigraphy in the detection of recurrent colorectal cancer. Nucl Med Commun 2001; 22:1295–304PubMedCrossRefGoogle Scholar
  22. 22.
    Verwaal VJ, van Ruth S, Witkamp A, et al. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005; 12:65–71PubMedCrossRefGoogle Scholar
  23. 23.
    Verwaal VJ, van Tinteren H, van Ruth S, et al. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 2004; 91:739–46PubMedCrossRefGoogle Scholar
  24. 24.
    Verwaal VJ, van Tinteren H, van Ruth, et al. Toxicity of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol 2004; 85:61–7PubMedCrossRefGoogle Scholar
  25. 25.
    Smeenk RM, Verwaal VJ, Zoetmulder FA. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 2007; 94:1408–14PubMedCrossRefGoogle Scholar
  26. 26.
    Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2007; 14:128–33PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  • Vic J. Verwaal
    • 1
  • Sjoerd Bruin
    • 1
  • Henk Boot
    • 2
  • Gooike van Slooten
    • 1
  • Harm van Tinteren
    • 3
  1. 1.Department of SurgeryThe Netherlands Cancer InstituteAmsterdamThe Netherlands
  2. 2.Department of GastroenterologyThe Netherlands Cancer InstituteAmsterdamThe Netherlands
  3. 3.Statistical DepartmentThe Netherlands Cancer InstituteAmsterdamThe Netherlands

Personalised recommendations